AUTHOR=Wu Xuan , Li Run Yun , Ye Xiao Bin , Wang Ning 

TITLE=Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China

JOURNAL=Frontiers in Neurology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.1072861

DOI=10.3389/fneur.2022.1072861

ISSN=1664-2295

ABSTRACT=<sec><title>Aims</title><p>To explore the quality of life (QOL) in patients with myasthenia gravis (MG) and factors associated with QOL.</p></sec><sec><title>Methods</title><p>This observational study included patients with MG diagnosed at the First Affiliated Hospital of Fujian Medical University between January 2020 and March 2022. The QOL of patients was evaluated with the 15-item Myasthenia Gravis Quality of Life (MG-QOL15). Current MG severity was evaluated with MGFA grade, MG-ADL score, MGC score, and MGFA Postintervention Status. The data about gender, age of onset, subgroup, antibodies, age, duration, education, employment state, marital status, skeletal muscle affected, thymic histology, and current treatment methods of the patient were collected.</p></sec><sec><title>Results</title><p>A total of 185 patients [72 males (38.9%), aged 45.2 years (14–77)] with MG were enrolled. Age at onset was 38.3 ± 17.9 years, and disease duration was 87.9 months (0–672). The median MG-QOL15 score was 12.5 (0–58). The item “have trouble using my eyes” was the highest scoring item in both ocular and generalized patients with MG. The MG-QOL15 score was significantly different among patients with OMG (9.2 ± 9.4, <italic>n</italic> = 63), GMG (9.0 ± 8.8, <italic>n</italic> = 22), and BMG (15.4 ± 14.2, <italic>n</italic> = 100) (<italic>P</italic> = 0.018). Patients with BMG had higher MG-QOL15 scores than OMG (<italic>P</italic> = 0.001) and GMG (<italic>P</italic> = 0.009), but there was no significant difference between OMG and GMG (<italic>P</italic> = 0.467). The MG-QOL15 score was significantly lower in patients who had undergone thymectomy (9.7 ± 9.8, <italic>n</italic> = 58) compared to those who had not (13.8 ± 13.4, <italic>n</italic> = 127, <italic>P</italic> = 0.022). MG-QOL15 score was significantly lower in patients who underwent thymectomy compared to those who did not (9.7 ± 9.8, <italic>n</italic> = 58 vs. 13.8 ± 13.4, <italic>n</italic> = 127, <italic>P</italic> = 0.022). MG-QOL15 score was different among MGFA grades (Remission: 5.2 ± 5.4, <italic>n</italic> = 41; I: 11.3 ± 10, <italic>n</italic> = 61; II: 11.6 ± 11.1, <italic>n</italic> = 40; III: 18.1 ± 12.1, <italic>n</italic> = 29; and IVa: 30.1 ± 20, <italic>n</italic> = 14, <italic>P</italic> &lt; 0.001). There was no significant difference between patients in MGFA grade I and II (<italic>P</italic> = 0.896), and there was no significant difference between patients in MGFA grade III and IVa (<italic>P</italic> = 0.052). MG-ADL (<italic>P</italic> &lt; 0.001) and MGC (<italic>P</italic> &lt; 0.001) were positively correlated with MG-QOL15. Men had higher MG-QOL15 than women (<italic>P</italic> = 0.094), and LOMG had higher MG-QOL15 than EOMG (<italic>P</italic> = 0.072). Multivariate linear regression identified that higher MG-ADL (<italic>P</italic> &lt; 0.001), higher MGC (<italic>P</italic> = 0.02), and poor employment status (<italic>P</italic> = 0.045) were independently associated with higher MG-QOL15.</p></sec><sec><title>Conclusion</title><p>Having trouble using the eyes accounted for the highest score in MG-QOL15, eye symptoms affect QOL more than limb weakness in MG. Daily life activity, disease severity, and employment status were associated with patients' QOL. Adequate treatment should be applied to improve QOL, while mild symptoms can be accepted. Men and patients over the age of 50 years of onset may need more attention.</p></sec>